CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients

CorMedix Inc.

LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.
CorMedix amended existing agreement with LDO customer to reflect anticipated increased product use.
Q2 2025 net sales guidance raised from $31M to $35-40M; modest revenue contribution expected in June with growth through H2 2025.
CEO cites implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.